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Abstract  
Objective: To investigate the effect of adding 
metformin to clomiphene citrate (CC) in 
polycystic ovarian syndrome (PCOS) patients 
with acanthosis nigricans (AN) who were 
previously not responding to CC. 
Material and Methods: A double blinded 
randomized controlled trial (NCT02562664) 
included 66 PCOS women with acanthosis 
nigricans who were CC resistant (at least 3 
months). Day 3 follicle stimulating hormone 
(FSH) level, fasting insulin, fasting glucose and 
homeostatic model assessment were used to 
quantify insulin resistance. Participants were 
randomly assigned to either group I (CC with 
placebo tablets) or group II (CC with metformin) 
for three cycles. Insulin resistance parameters 
as well as clinical pregnancy rate had been 
evaluated in both groups. The statistical analysis 
was done using Chi- square and Fischer exact 
tests.  
Results: The demographic data was comparable 
in both groups, however; there was higher 
cumulative pregnancy rate after three cycles of 
stimulation in group II (18/33) (54.5%) in 
comparison with group I (7/33) (21.1%) 
(P=0.03). There was a significant improvement 
in the insulin resistance parameters after three 
months of combining clomiphene citrate with 
metformin as compared with CC alone.  
Conclusion: Adding metformin to CC in 
clomiphene citrate resistant PCOS patients who 
have acanthosis nigricans improves the 
pregnancy rate and insulin resistant parameters. 
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Introduction 
Polycystic ovary syndrome (PCOS) is 
the most common female endocrine 
disorder, with a prevalence ranging 
between 6% to 10% based on the 
National Institutes of Health (NIH) 
criteria. When the broader Rotterdam 
criteria are applied; the prevalence 
reaches as high as 15%.1 The typical 
presentation of POCS includes ovarian 
dysfunction (anovulation), 
hyperandrogenism (either clinical or 
biochemical), and the ultrasonographic 
picture of polycystic ovaries.2 The 
etiology of the syndrome is still unclear 
and the variability in clinical presentation 
continues to make the clinical and 
research implications challenging.3  
Insulin resistance is a common finding in 
obese women with PCOS.4 The cellular 
and molecular mechanisms of insulin 
resistance in PCOS differ from other 
common insulin-resistant states such as 
obesity and type 2 diabetes mellitus 
(DM).5 PCOS and obesity both have a 
negative effect on insulin action.6 
Pancreatic b-cell dysfunction is also 
present in PCOS but may be more 
related to type 2 DM risk factors such as 
women having first-degree relative with 
the DM.7 
Acanthosis nigricans (AN) is a skin 
disease characterized by velvety, 
papillomatous, brownish-black and 
hyperkeratotic plaques. Typically it 
presents at intertriginous surfaces and 
the neck. AN is usually associated with 
obesity, insulin resistance and PSOS.8 
Hyperkeratosis is increased in melanin 
pigmentation resulting in the dark color 
of AN.9 There is a subtle infiltrate 
composed of lymphocytes, plasma cells, 
and neutrophils as well as horn 
pseudocyst formation. Colloidal iron 
tissue staining often exhibits infiltration 
of the papillary dermis with 
glycosaminoglycans such as hyaluronic 
acid, especially in patients with PCOS.10  
Elevated insulin concentrations result in 
direct and indirect activation of insulin-
like growth factor 1 (IGF-1) receptors on 
keratinocytes and fibroblasts, leading to 
its proliferation. Other mediator’s 
receptors may also contribute, including 
Epidermal Growth Factor Receptor 
(EGFR) and Fibroblast Growth Factor 
Receptor (FGFR).11 Hyperinsulinemia 
may also facilitate the development of 
AN indirectly by increasing the levels of 
free IGF-1 in the circulation.12  Insulin-
like growth factor 1 binding protein and 
insulin-like growth factor 2 binding 
protein are decreased in obese women 
with hyperinsulinemia leading to an 
increase in plasma concentrations of 
free IGF-1.13  
Metformin has a great effect on PCOS 
patients. This may be due to a reduction 
of pituitary secretion of LH, a reduction 
of ovarian secretion of androgens, a 
reduction of adrenal secretion and finally 
an increased level of sex hormone 
binding globulin.14 Obesity is usually 
associated with hyperinsulinemia which 
is responsible for the low 
responsiveness of PCOS patients to 
clomiphene citrate.15 A significant 
improvement in ovulation and 
pregnancy rates was reported when 
adding metformin to clomiphene citrate 
in clomiphene-resistant PCOS 
patients.16  
The current study reviews the effect of 
adding metformin to clomiphene citrate 
in PCOS patients with acanthosis 
nigricans (AN) who were previously did 
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not respond to CC alone. We 
hypothesized that adding metformin to 
this special group of women, AN 
patients with insulin resistance, may be 
beneficial for them including an 
improvement in pregnancy rate and 
hyperinsulinemia parameters. 
Materials and Methods 
The current study is a clinically 
registered double blinded, parallel, RCT 
(NCT02562664) compassing the effect 
of adding metformin to CC in PCOS 
patients who had acanthosis nigricans. 
The ethical review board of the Faculty 
of Medicine of the Assiut University 
approved the study. The participants 
were recruited from the Outpatient 
Infertility Clinic of the Woman’s Health 
Hospital. It was carried out in the period 
between the first of August 2013 and the 
first of November 2014. This trial was 
designed and reported according to the 
revised recommendation of 
ClinicalTrials.gov for improving the 
quality of reporting RCTs.  
Eligible participants 
All participants who presented to the 
above clinic with acanthosis nigricans 
associated PCOS and previously not 
responding to CC were recruited in the 
study. The patient was considered 
eligible if she was under age 40 year, 
fulfilled at least 2 out of the three criteria 
of Rotterdam consensus 2003 and had 
AN. All participants had unsatisfactory 
ovulation after at least 3 months of CC 
induction. We excluded women with any 
contraindications to metformin such as 
liver disease, heart or respiratory failure, 
alcohol abuse, and kidney disease.  All 
couples signed an informed consent to 
participate in the study.  
Randomization 
Randomization was done using a 
computer-generated random table. The 
participants who consented were 
randomly assigned to receive either CC 
with placebo or CC with metformin. 
Allocation concealment was done using 
serially numbered closed opaque 
envelopes. Each envelope was labeled 
with a serial number and had a card 
showing the intervention type inside. 
Allocation was never changed after 
opening the envelopes (study flow chart, 
Fig. 1). 
Intervention 
All study participants had proper clinical 
evaluation to ensure the diagnosis of AN 
(by assistant professor of dermatology 
D.A.A). Additionally, day 3 follicle 
stimulating hormone (FSH) level, fasting 
insulin, fasting glucose and homeostatic 
model assessment, to quantify insulin 
resistance (HOMA –IR), were done. 
Eligible participants were allocated to 
one of two groups. Group I received 100 
mg clomiphene citrate (Clomid, global 
Napi , Egypt) from day 3 to day 7 of the 
cycle with placebo tablets which were 
taken twice daily continuously for three 
cycles. Group II received the above CC 
dose plus metformin (Cidophage , Amon 
, Egypt) 500 mg twice daily continuously 
for three cycles. Insulin resistance 
parameters as well as clinical pregnancy 
rate had been evaluated in both groups. 
The participants were requested to 
come to a monthly follow-up in our clinic 
for 3 months. Each participant had a 
special follow-up card that included the 
study serial number, the study group 
and the required follow-up schedule.  
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Figure 1: The study flow chart 
 
Assessed for eligibility (n=75) 
Excluded (n=9) 
• Not meeting inclusion criteria (n=6) 
• Declined to participate (n=3) 
Randomized (n=66) 
Allocated to intervention (n=33) 
Received CC with metformin 
 
Allocated to intervention (n=33) 
Received CC with placebo 
 
    
Allocation 
Follow-Up 
• Clinical (pregnancy rate) 
• Biochemically (fasting insulin, fasting glucose and 
   
Analyzed (n=33) Analyzed (n=33) 
Analysis 
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Study outcomes 
The primary outcome of this study was 
the cumulative pregnancy rate after 3 
months of treatment. Secondary 
outcomes included improvement of 
insulin resistance parameters such as 
fasting insulin, fasting glucose and 
homeostatic model assessment (HOMA 
–IR). 
Follow-up schedule 
All study participants were followed at 
the end of the first, second and third 
months from the start of treatment. 
During each visit, we evaluated the 
patients clinically; we asked them to 
report their last menstrual period to 
ensure the pregnancy occurrence. 
When pregnancy occurred, 2D 
ultrasound was done to evaluate 
number of pregnancies. Finally, the 
insulin resistance parameters were 
assessed at the end of third month. 
Sample size 
The sample size calculation was based 
on the primary outcome (cumulative 
pregnancy rate). Previous randomized 
studies reported that the CC with 
metformin improved pregnancy rate 
from 8% to 24% after using CC with 
metformin.17 Using a two-sided chi-
square (χ2) test with an α of 0.05, a total 
sample size was calculated to be at 
least 66 patients in the 2 groups (33 in 
each arm) with 80% power assuming a 
rate of loss to follow-up of 10% (Epi-
info™, Centers for Disease Control and 
Prevention, USA). 
Statistical analysis 
The data were collected and entered 
into a Microsoft Access database and 
were analyzed using the Statistical 
Package for Social Science (SPSS Inc., 
Chicago, version 16). The demographic 
characteristics and baseline data were 
compared between both groups. The 
outcome variables were calculated 
using a paired t test to compare 
continuous variables before and after 
treatment and using an unpaired t test 
between groups. For dichotomous 
variables, chi-square was used to 
estimate the significance value. For 
analysis, p>.05 was considered to be 
significant.  
Results 
Out of 75 recruited patients, 66 
consented to participate. Of those nine 
women; three did not meet the inclusion 
criteria and six women were not willing 
to participate in an RCT. Basal 
characteristics of the study participants 
are given in Table 1 and showed that 
the two study groups were similar in 
mean age, duration of infertility, weight 
and height. Moreover; the studied 
women were also similar in the ovarian 
volume, antral follicle count (AFC), FSH, 
LH and prolactin (Table 1).   
There were significant improvements in 
the insulin resistance parameters after 
three months of combining CC and 
metformin when compared with CC 
alone. After 3 months of treatment 
patients of group II had statistically 
significant improvement of fasting 
glucose (P value=0.001), fasting insulin 
(p value= 0.005) and HOMA- IR (P 
value= 0.001) (Table 3 and 4). 
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Table 1: Patient demographic data 
  Group I 
(CC+ placebo) 
n=33 
Group II 
(CC+ 
metformin) 
n=33 
 
P. value 
Mean SD Mean SD 
Age (years) 26.12 5.24 24.91 3.34 0.05 
Duration of infertility(years) 5.00 3.10 3.94 1.70 0.05 
Wt (Kg) 78.03 8.11 78.58 8.18 0.787 
Ovarian  Volume(mL) 11.97 2.37 11.32 1.87 0.220 
Galactorrhea 0.33 0.48 0.27 0.45 0.599 
AFC 13.15 1.72 13.39 2.03 0.602 
FSH(MIU) 5.50 1.34 5.44 1.73 0.866 
LH(MIU) 10.12 2.20 10.42 1.88 0.558 
Prolactin(ng/mL) 16.11 5.23 15.34 5.72 0.571 
Endometrial thick(mm) 8.69 2.04 9.04 2.27 0.515 
Number of follicles at cycle 1 2.00 0.82 1.89 0.92 0.657 
Number of follicles at cycle 2 1.77 0.76 2.04 0.94 0.261 
Number of follicles at cycle 3 1.70 0.63 1.96 1.00 0.270 
Progesterone day 21(ng/ml) 14.79 6.33 14.95 4.67 0.932 
Wt weight, AFC antral follicle count, FSH follicular stimulating hormone, LH luteinized hormone 
Table 2: Cumulative pregnancy rate after 3 months of treatment 
  Group I 
(CC+ placebo) 
n=33 
Group II 
(CC+ metformin) 
n=33 
 
P. value 
No. % No. % 
PR from cycle 1 2 6.1 3 9.1 NS  
Singleton 2 6.1 0 0.0 NS   
Twin 0 0.0 3 9.1 NS   
Abortion 0 0% 1 3% NS  
PR from cycle 2 5 15.2 12 36.4       NS 
Singleton 4 12.2 10 30.3 NS   
Twin 1 3.0 2 6.1 NS   
Abortion 0 0% 1 3% NS  
PR from cycle 3            
Abortion 0 0 % 1 3% NS   
Three cycles PR 7 21.2 18 54.5 0.033* 
*Statistically significant difference (p<.05).  PR pregnancy rate 
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Table 3: Insulin parameters before treatment 
  
Group I 
(CC+ placebo) 
n=33 
 
Group II 
(CC+ metformin) 
n=33 
 
 
 
P. value 
          
Mean 
 
  SD 
 
Mean 
 
SD 
Fasting glucose( mg/dL) 102.12 8.85 99.70 9.23 0.280 
Fasting insulin (mg/dL) 11.57 2.73 12.60 3.91 0.364 
HOMA_IR (mg/dL) 2.88 0.63 3.07 0.87 0.467 
Progesterone D 21(ng/ml) 14.79 6.33 14.95 4.67 0.932 
HOMA_IR homeostatic model assessment of insulin resistance 
Table 4: Insulin parameters after 3 months treatment 
 Group I 
(CC+ placebo) 
n=33 
 Group II 
(CC+ metformin) 
n=33 
  
P. value 
 Mean SD Mean SD  
Fasting glucose( mg/dL) 96.85 6.84 89.76 6.22 0.001* 
 
Fasting insulin( mg/dL)
  
12.06 3.12 7.83 2.95 0.005* 
HOMA_IR( mg/dL) 2.90 0.71 1.72 0.67 0.001* 
*Statistically significant difference (p<.05). HOMA_IR homeostatic model assessment of insulin resistance 
Discussion 
Our data showed that adding metformin 
to clomiphene citrate for three cycles of 
ovulation induction in PCOS patients 
resistant to clomiphene citrate with 
acanthosis nigricans not only improved 
the cumulative pregnancy rate but also 
the insulin resistance parameters e.g. 
fasting insulin, fasting glucose and 
HOMA-IR.  
 Acanthosis nigricans is one of the 
clinical parameters indicating insulin 
resistance especially in patients with 
PCOS.9 Hence, the basis for the 
hypothesis that AN patients would 
benefit from the addition of metformin to 
clomiphene citrate by increasing 
glucose hepatic utilization accompanied 
by an improved metabolic profile, a 
significant reduction in 
hyperandrogenemia, and an 
improvement in ovulation and 
menstruation pattern.18  
In developing countries where it is 
financially prohibitive to perform the 
insulin parameters for all clomiphene 
citrate resistant patients, AN can be 
used as clinical sign indicating insulin 
resistance and thus recommending the 
addition of metformin to clomiphene 
citrate in their treatment protocol.  
The same data were published by 
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Neveu et al. who proved that metformin 
is better for ovulation induction than CC 
alone and they suggested using of 
metformin as a first line for ovulation 
induction in patients with PCOS 
regardless of their weight and insulin 
levels. However; they found no 
significant difference in the pregnancy 
achievement which differs from our 
study as we found more cumulative 
pregnancy rate with using CC with 
metformin.19 Our results were in 
agreement with data published by 
Khorram et al. who concluded that 
adding metformin with CC reduced 
serum insulin, insulin resistance and 
increased SHBG levels, resulting in an 
improved response to CC.20  
Ben Ayed and colleagues support our 
results because they found a significant 
improvement of the ovulatory response 
to clomiphene citrate in PCOS women 
when adding metformin.21 The same 
results were also observed by Dasari et 
al. who reported that the ovulatory rate 
and the pregnancy rate with the 
metformin-CC combination was higher 
when compared with CC alone.17 
The conclusion of the systematic review 
conducted by Siebert et al. is that CC 
alone is superior to metformin alone 
regarding live birth rate and ovulation. 
The combination (CC+ metformin) is 
superior to CC alone as a primary 
method for ovulation induction and to 
achieve pregnancy in PCOS.22 Kar et al. 
reported similar results and proved that 
metformin is as good as CC in terms of 
live birth rate and the combination of CC 
and metformin gave the highest 
ovulation and live birth rate.23 The last 
published study was by Shigiyama et al. 
in 2016 who successfully treated a lean 
PCOS patient with type 1 diabetes by 
metformin. However; they concluded 
that the hyperinsulinemia associated 
with type 1 diabetes potentially 
exacerbates PCOS through 
hyperandrogenism. Therefore, 
metformin is recommended for lean 
PCOS with type 1 diabetes as well as 
for common obese PCOS with type 2 
diabetes.24 
Rosiglitazone is another insulin 
sensitizer that acts through increased 
production of insulin-sensitive 
adipocytes and increased glucose 
uptake. Many published studies suggest 
using it in PCOS due to its beneficial 
effect on hyperandrogenism, insulin 
resistant and anovulation in both lean 
and obese women with PCOS.25 Yilmaz 
et al. found that both metformin and 
rosiglitazone increased insulin sensitivity 
in obese and lean patients with PCOS 
and they also found that rosiglitazone 
seemed to be more effective in 
decreasing the androgen levels and in 
achieving a slightly higher improvement 
in menstrual disturbance than 
metformin.26 Dereli et al. demonstrated 
in their study that rosiglitazone improved 
the ovulatory dysfunction, hirsutism, 
hyperandrogenemia, and insulin 
resistance of PCOS with minimal 
adverse effects. In addition; this drug 
may be a good choice for patients with 
PCOS, especially for the ones who 
failed to show satisfactory results in 
metformin therapy.27  
It was noticed that the gastrointestinal 
side effects of metformin were 
dramatically improved when the patients 
used them during meals as 
recommended by previous studies.28 
This improvement enabled us to 
continue using metformin with CC for 
three successive months.  
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In our study we selected patients with 
acanthosis nigricans assuming that 
those patients would have more 
response to the addition of metformin to 
CC for three cycles of stimulation. 
Limitations of our study include small 
sample size and not evaluating the 
effect of metformin on improving AN 
from the dermatological perspective. 
Still more data is needed to support the 
effect of insulin sensitizers on improving 
the pregnancy rate in the CC resistance 
PCOS patients who have acanthosis 
nigricans. 
Conclusion 
The addition of metformin to CC in 
clomiphene citrate resistant PCOS 
patients who have acanthosis nigricans 
improves both pregnancy rate and 
hyperinsulinemia parameters. 
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